pI: 9.5369 |
Length (AA): 616 |
MW (Da): 72530 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
186 | 405 | 1kg2 (A) | 1 | 220 | 31.00 | 0.000000000077 | 1 | 0.859643 | -1.03 |
190 | 404 | 3n5n (X) | 89 | 303 | 35.00 | 0.0000000031 | 1 | 0.836526 | -0.58 |
200 | 399 | 1kea (A) | 20 | 219 | 27.00 | 0.00024 | 1 | 0.689175 | -0.25 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Ookinete. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | 4 hs Ring, 16 hs Trophozoite, Erthyrocytic stages, Male gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | Gametocyte, 22 hs Schizont, Female gametocyte. | Otto TD Yeoh LM |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Ortholog group members (OG5_128159)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G12740 | HhH-GPD base excision DNA repair family protein |
Chlamydia trachomatis | CT_107 | A/G-specific adenine glycosylase |
Dictyostelium discoideum | DDB_G0270764 | A/G-specific adenine DNA glycosylase |
Escherichia coli | b2961 | adenine DNA glycosylase |
Entamoeba histolytica | EHI_010700 | A/G-specific adenine glycosylase, putative |
Homo sapiens | ENSG00000132781 | mutY homolog |
Leishmania braziliensis | LbrM.28.2340 | A/G-specific adenine glycosylase, putative |
Leishmania donovani | LdBPK_282290.1 | A/G-specific adenine glycosylase, putative |
Leishmania infantum | LinJ.28.2290 | A/G-specific adenine glycosylase, putative |
Leishmania major | LmjF.28.2140 | A/G-specific adenine glycosylase, putative |
Leishmania mexicana | LmxM.28.2140 | A/G-specific adenine glycosylase, putative |
Mycobacterium leprae | ML1920 | PROBABLE ADENINE GLYCOSYLASE MUTY |
Mus musculus | ENSMUSG00000028687 | mutY homolog (E. coli) |
Mycobacterium tuberculosis | Rv3589 | Probable adenine glycosylase MutY |
Mycobacterium ulcerans | MUL_4165 | adenine glycosylase MutY |
Neospora caninum | NCLIV_056760 | helix-hairpin-helix motif-containing protein, putative |
Oryza sativa | 4351781 | Os12g0211400 |
Plasmodium berghei | PBANKA_0918700 | A/G-specific adenine glycosylase, putative |
Plasmodium falciparum | PF3D7_1129500 | A/G-specific adenine glycosylase, putative |
Plasmodium knowlesi | PKNH_0927500 | A/G-specific adenine glycosylase, putative |
Plasmodium vivax | PVX_092090 | A/G-specific adenine glycosylase, putative |
Plasmodium yoelii | PY05666 | A/G-specific adenine glycosylase, putative |
Schistosoma japonicum | Sjp_0031390 | ko:K03575 A/G-specific adenine glycosylase, putative |
Schistosoma mansoni | Smp_001020 | DNA glycosylase |
Trypanosoma brucei gambiense | Tbg972.11.12830 | A/G-specific adenine glycosylase, putative |
Trypanosoma brucei | Tb927.11.11440 | A/G-specific adenine glycosylase, putative |
Trypanosoma congolense | TcIL3000_0_22020 | A/G-specific adenine glycosylase, putative |
Trypanosoma cruzi | TcCLB.511803.20 | A/G-specific adenine glycosylase, putative |
Toxoplasma gondii | TGME49_313470 | helix-hairpin-helix motif domain-containing protein |
Treponema pallidum | TP0343 | A/G-specific adenine glycosylase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu3651 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb11.01.3270 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.3270 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.3270 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.01.3270 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b2961 | Escherichia coli | non-essential | goodall |
PBANKA_0918700 this record | Plasmodium berghei | Dispensable | plasmo |
TGME49_313470 | Toxoplasma gondii | Probably non-essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.